PL2634185T3 - Inhibitory kinazy TYK2 - Google Patents

Inhibitory kinazy TYK2

Info

Publication number
PL2634185T3
PL2634185T3 PL13157419T PL13157419T PL2634185T3 PL 2634185 T3 PL2634185 T3 PL 2634185T3 PL 13157419 T PL13157419 T PL 13157419T PL 13157419 T PL13157419 T PL 13157419T PL 2634185 T3 PL2634185 T3 PL 2634185T3
Authority
PL
Poland
Prior art keywords
kinase inhibitors
tyk2 kinase
tyk2
inhibitors
kinase
Prior art date
Application number
PL13157419T
Other languages
English (en)
Inventor
John Charles Reader
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of PL2634185T3 publication Critical patent/PL2634185T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13157419T 2012-03-02 2013-03-01 Inhibitory kinazy TYK2 PL2634185T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605952P 2012-03-02 2012-03-02
EP13157419.6A EP2634185B1 (en) 2012-03-02 2013-03-01 TYK2 kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2634185T3 true PL2634185T3 (pl) 2016-06-30

Family

ID=47754367

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13157419T PL2634185T3 (pl) 2012-03-02 2013-03-01 Inhibitory kinazy TYK2

Country Status (5)

Country Link
US (3) US20130231340A1 (pl)
EP (2) EP2634185B1 (pl)
DK (2) DK3040336T3 (pl)
ES (1) ES2566205T3 (pl)
PL (1) PL2634185T3 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
PL2634185T3 (pl) 2012-03-02 2016-06-30 Sareum Ltd Inhibitory kinazy TYK2
AU2013399913B2 (en) * 2013-09-03 2018-03-15 Sareum Limited Pharmaceutical compounds
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
AU2017378398B2 (en) 2016-12-14 2023-02-02 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
CA3055209A1 (en) 2017-03-08 2018-09-13 Nimbus Lakshmi, Inc. Tyk2 inhibitors, uses, and methods for production thereof
SG11202010092XA (en) * 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
JPS56159794A (en) 1980-05-12 1981-12-09 Tokyo Optical Length or angle measuring device
JPH0753716B2 (ja) 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
EE200200715A (et) 2000-06-28 2004-08-16 Astrazeneca Ab Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
DK1392291T3 (da) 2000-10-30 2007-10-08 Janssen Pharmaceutica Nv Tripeptidylpeptidaseinhibitorer
WO2004005283A1 (en) 2002-07-09 2004-01-15 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
US7947707B2 (en) 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
JP2011518221A (ja) 2008-04-21 2011-06-23 メルク・シャープ・エンド・ドーム・コーポレイション Janusキナーゼの阻害剤
US8344144B2 (en) 2008-06-18 2013-01-01 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
JP2011527680A (ja) 2008-07-09 2011-11-04 メルク・シャープ・エンド・ドーム・コーポレイション Janusキナーゼの阻害剤
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2012323399A1 (en) 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
PL2634185T3 (pl) 2012-03-02 2016-06-30 Sareum Ltd Inhibitory kinazy TYK2
GB201617871D0 (en) * 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
EP3040336A1 (en) 2016-07-06
US20190210983A1 (en) 2019-07-11
EP2634185B1 (en) 2016-01-13
DK2634185T3 (en) 2016-03-21
ES2566205T3 (es) 2016-04-11
EP3040336B1 (en) 2020-04-08
US20130231340A1 (en) 2013-09-05
EP2634185A1 (en) 2013-09-04
US20210087154A1 (en) 2021-03-25
DK3040336T3 (da) 2020-06-22
US11673870B2 (en) 2023-06-13
US10882829B2 (en) 2021-01-05

Similar Documents

Publication Publication Date Title
IL261282A (en) Furinone compounds as kinase inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201508847B (en) Serine/threonine kinase inhibitors
PL2710007T3 (pl) Inhibitory kinazy
ZA201404156B (en) Kinase inhibitors
EP2831080A4 (en) LACTAMES INHIBITORS OF KINASES
SI2903618T1 (sl) Zaviralci RHO kinaze
PL2634185T3 (pl) Inhibitory kinazy TYK2
IL229028A0 (en) Kinase inhibitors
EP2900668A4 (en) INHIBITORS OF MULTIPLE KINASE PATHWAYS
IL228103A0 (en) Amino-quinolines as kinase inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
ZA201409256B (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
EP2870158A4 (en) PROTEIN KINASE INHIBITORS
IL232701A0 (en) Pyrazine kinase inhibitors
ZA201404157B (en) Kinase inhibitors
EP2855484A4 (en) PROTEIN KINASE INHIBITORS
EP2900243A4 (en) BICYCLIC OXA LACTAM KINASE HEMMER